Pacibekitug
$1.4 Billion Deal: Novartis Buys Tourmaline Bio and Its Phase 3-Ready IL-6 Antibody Pacibekitug
Novartis acquired Tourmaline Bio for $1.4B, gaining pacibekitug (TOUR006), a Phase 3-ready anti-IL-6 IgG2 mAb. Discovered via Pfizer and Medarex’s UltiMAb® platform, it shows up to 86% hs-CRP reduction and targets residual inflammatory risk in ASCVD.